<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03849495</url>
  </required_header>
  <id_info>
    <org_study_id>191BE18033</org_study_id>
    <nct_id>NCT03849495</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-370 and D745 in Healthy Adults</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, Two-way Crossover Study to Compare the Pharmacokinetics and Safety/Tolerability of CKD-370 With D745 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, open-label, single dose, two-way crossover study to compare the
      pharmacokinetics and safety/tolerability of CKD-370 with D745 in healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2019</start_date>
  <completion_date type="Anticipated">March 21, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 17, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast of Empagliflozin</measure>
    <time_frame>0 hour ~ 48 hour after drug administration</time_frame>
    <description>Area under the plasma concentration-time curve to last concentration of Empagliflozin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Empagliflozin</measure>
    <time_frame>0 hour ~ 48 hour after drug administration</time_frame>
    <description>Maximum plasma concentration of Empagliflozin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Empagliflozin</measure>
    <time_frame>0 hour ~ 48 hour after drug administration</time_frame>
    <description>Area under the plasma concentration-time curve from zero to infinity concentration of Empagliflozin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Empagliflozin</measure>
    <time_frame>0 hour ~ 48 hour after drug administration</time_frame>
    <description>Time to maximum plasma concentration of Empagliflozin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of Empagliflozin</measure>
    <time_frame>0 hour ~ 48 hour after drug administration</time_frame>
    <description>Half-life of Empagliflozin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Empagliflozin</measure>
    <time_frame>0 hour ~ 48 hour after drug administration</time_frame>
    <description>Apparent clearance of Empagliflozin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of Empagliflozin</measure>
    <time_frame>0 hour ~ 48 hour after drug administration</time_frame>
    <description>Apparent volume of distribution of Empagliflozin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: D745
Period 2: CKD-370</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-370
Period 2: D745</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-370</intervention_name>
    <description>Test drug</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D745</intervention_name>
    <description>Reference drug</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adults aged 19 to 55 years

          2. Females who are not pregnant or breastfeeding or who have surgical infertility

          3. Signed informed consent form

          4. Other inclusion criteria, as defined in the protocol

        Exclusion Criteria:

          1. History of clinically significant hepatic, renal, nervous, immune, respiratory,
             digestive, urinary, endocrine, hemato-oncology, cardiovascular systemic disease or
             psychosis disorder

          2. Clinical laboratory test values are outside the accepted normal range at Screening

               -  aspartate aminotransferase(AST), alanine aminotransferase(ALT) &gt; 1.5 times the
                  upper limit of the normal range

               -  Total Bilirubin &gt; 1.5 times the upper limit of the normal range

               -  creatine phosphokinase(CPK) &gt; 1.5 times the upper limit of the normal range

               -  estimated Glomerular Filtration Rate(eGFR, MDRD* formula) &lt; 60 mL/min/1.73m2
                  (*MDRD: Modification of Diet in Renal Disease)

               -  Positive reaction on following tests: Hepatitis B, Hepatitis C, human
                  immunodeficiency virus(HIV) and syphilis

               -  systolic blood pressure(SBP) â‰¥ 150 mmHg or &lt; 90 mmHg, diastolic blood
                  pressure(DBP) &gt; 100 mmHg or &lt; 50 mmHg

          3. Current smokers or those who cannot quit smoking during the period from 90 days before
             the first IP dosing to the last discharge.

          4. Subject who drink excessive caffeine or alcohol continuously and who cannot
             discontinue caffeine or alcohol intake during the period from 3 days before the first
             IP dosing to the last discharge.

          5. Participated in a clinical trial within 90 days prior to first IP dosing

          6. Not eligible to participate for the study at the discretion of Investigator

          7. Other exclusive inclusion criteria, as defined in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung Sang Yu, Ph.D. M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kyung Sang Yu, Ph.D. M.D.</last_name>
    <phone>+82-2-2072-1920</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deok Yong Yoon</last_name>
    <phone>+82-2-2072-1930</phone>
    <email>dyyoon18@snu.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyung Sang Yu, Ph.D. M.D.</last_name>
      <phone>+82-2-2072-1920</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 20, 2019</study_first_submitted>
  <study_first_submitted_qc>February 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2019</study_first_posted>
  <last_update_submitted>March 10, 2019</last_update_submitted>
  <last_update_submitted_qc>March 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

